Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.

NCT02698410 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Neuroendocrine Tumours

Interventions

DRUG: Lanreotide (Autogel formulation) and Temozolomide

Sponsor

Ipsen